Select Your Region
Americas
Europa
Afrika
Weltweit
Eine Studie zur Untersuchung der Sicherheit eines Medikaments namens Bevacizumab, welches Patienten mit verschiedenen Krebsarten über einen längeren Zeitraum erhielten
Eine Verlängerungsstudie, um Teilnehmenden mit soliden Tumoren, die zuvor an einer von Roche/Genentech gesponserten Studie teilgenommen haben, weiterhin eine Bevacizumab-Therapie bereitzustellen
- Krebs
- Tumor
- Neoplasien
Bitte beachten Sie, dass der Rekrutierungsstatus der Studie an Ihrem Standort vom Gesamtstatus der Studie abweichen kann, da einige Studienzentren früher rekrutieren als andere.
Status der Studie:
Abgeschlossen
Diese Studie läuft in
Städte
- Frankfurt am Main
- Großhansdorf
Studien-ID:
NCT01588184 2011-002009-31 MO25757
Studienzusammenfassung
This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
Hoffmann-La Roche
Sponsor
Phase 4
Phase
NCT01588184,MO25757,2011-002009-31
Studien-ID
Bevacizumab
Treatments
Neoplasms
Condition
Official Title
A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study
Einschlusskriterien
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator
- Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol
- Able to comply with this extension study protocol (MO25757)
Exclusion Criteria
- Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study
- Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation
- A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial
- Evidence of any other disease that would put the participant at high risk for treatment-related complications
Um die aktuellste Version dieser Seite aufzurufen gehen Sie bitte auf www.Klinische-studien-für-patienten.de
